Pharmaceuticals News and Research

RSS

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.

21 Feb 2011

Sheffield Bio-Science forms strategic alliance with Wockhardt to strengthen cell culture media portfolio

Sheffield Bio-Science, a Kerry Group Business, has formed a strategic global sales, marketing and development alliance with Wockhardt Ltd. Under this partnership, Sheffield Bio-Science will be the Exclusive Global Sales and Distribution Partner for recombinant insulin manufactured by global Indian biotech Wockhardt. According to estimates, the potential in cell culture markets is around US$ 50 million.

21 Feb 2011

'Experience station' program offers rheumatologists to gain insight into patients' everyday challenges

Pharmaceutical companies are focusing on more unique approaches in the development of educational and experiential solutions for their health care customers at medical conferences, according to Joe Scrocco, chief executive officer of OneWorld, Inc., a leading pharmaceutical consulting firm.

21 Feb 2011

New blood pressure measurement device may enable doctors to treat patients more effectively

In a major scientific breakthrough, a new blood pressure measurement device is set to revolutionise the way patients' blood pressure is measured.

20 Feb 2011

CompanDX, CRL enter multi-year agreement to develop biomarker panels

CompanDX Ltd., bioinformatics partner for the life sciences industry, and Clinical Reference Laboratory, Inc. (CRL), provider of laboratory testing services in molecular diagnostics and clinical trials, today announced they entered into a multi-year agreement to collaborate in the development and support of biomarker panels and companion diagnostic development for pharmaceutical, biotech and academic clients worldwide.

19 Feb 2011

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the 2011 Genitourinary Cancers Symposium held in Orlando, Florida on February 17 – 19, 2011.

19 Feb 2011

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has been ranked seventh in the biotech industry in Fast Company's annual list of the world's most innovative companies in 2011.

19 Feb 2011

$Grifols to start construction of new plant in Spain for plasma fractionation$

Grifols to start construction of new plant in Spain for plasma fractionation

Grifols, the Spanish group which specializes in the hospital-pharmaceutical sector and is one of the world's leading producers of plasma products, will shortly start construction of a new plant representing an investment of 20 million euros that will employ about 100 people, as soon as it obtains local permits and licenses.

19 Feb 2011

MFA finds health insurance companies across the U.S. alter vendor management policies

Mark Farrah Associates, a leading provider of market data and intelligence solutions, found health insurance companies across the U.S. are altering their vendor management policies.

19 Feb 2011

Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting

Novavax, a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th World Health Organization Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials.

19 Feb 2011

Angiotech executes Settlement and License Termination Agreement with Rex Medical

Angiotech Pharmaceuticals, Inc. today announced that its subsidiary, Angiotech Pharmaceuticals, Inc., has executed a Settlement and License Termination Agreement with Rex Medical, LP, providing for the full and final settlement and/or dismissal of all claims arising under the the License, Supply, Marketing and Distribution Agreement between Angiotech US and Rex, dated March 13, 2008.

19 Feb 2011

Merck Canada announces $6.8 million investment in AmorChem for biopharmaceutical research

Merck Canada announced today a $6.8 million investment in AmorChem, a Quebec life sciences venture capital fund. This is the latest investment made by Merck following a commitment made in 2010 to invest an incremental $100 million over five years in biopharmaceutical research and development in Quebec.

19 Feb 2011

Impax' NDA for generic version of Adoxa receives final FDA approval

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration has granted final approval of the Company's Abbreviated New Drug Application for its generic version of Adoxa.

18 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

Cyclacel Pharmaceuticals, Inc., today announced the publication of preclinical data in the Proceedings of the National Academy of Sciences (PNAS), demonstrating that cyclin E plays a major role in making Human Epidermal growth factor Receptor 2 positive (HER2+) breast cancer resistant to trastuzumab (Herceptin®), a widely used medicine for breast cancer patients who test positive for HER2.

18 Feb 2011

DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

DiaGenic has significantly altered its business strategy during 2010 to leverage more effectively its commercial potential, and strengths in Intellectual Property (IP). The Company has made significant progress in its business activities towards big pharma since implementation of the new strategy. DiaGenic is well positioned as a multimodal partner with large pharma and imaging companies.

18 Feb 2011

Longer looks: KHN's best health policy picks from thought-provoking publications

A law under consideration in South Dakota would expand the definition of "justifiable homicide" to include killings that are intended to prevent harm to a fetus—a move that could make it legal to kill doctors who perform abortions.

18 Feb 2011

Report finds neglected diseases research funding up in 2009, funding for related non-profits down

"A rise in global funding for research into neglected diseases needs to be matched by a continued focus on delivering practical new ways to curb sickness in the developing world," according to the third annual report by the Global Funding of Innovation for Neglected Diseases released on Wednesday, Reuters reports.

18 Feb 2011

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals and Bioniche Life Sciences Inc. today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348.

18 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

Pharmaceuticals News and Research

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

Sheffield Bio-Science forms strategic alliance with Wockhardt to strengthen cell culture media portfolio

'Experience station' program offers rheumatologists to gain insight into patients' everyday challenges

New blood pressure measurement device may enable doctors to treat patients more effectively

CompanDX, CRL enter multi-year agreement to develop biomarker panels

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

Grifols to start construction of new plant in Spain for plasma fractionation

MFA finds health insurance companies across the U.S. alter vendor management policies

Novavax announces final safety, immunogenicity results from H1N1 VLP vaccine at WHO meeting

Angiotech executes Settlement and License Termination Agreement with Rex Medical

Merck Canada announces $6.8 million investment in AmorChem for biopharmaceutical research

Impax' NDA for generic version of Adoxa receives final FDA approval

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Cyclacel's CYC065 CDK inhibitor demonstrates potential against breast cancer resistant to trastuzumab

DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand

Longer looks: KHN's best health policy picks from thought-provoking publications

Report finds neglected diseases research funding up in 2009, funding for related non-profits down

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence